SCHEMBL22774372

SCHEMBL22774372

O=C(CCC(=O)c1ccccc1)NOCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.63
RAB9A P51151 6/20 0.63
ALDH1A1 P00352 2/20 0.59
HDAC3 O15379 1/20 0.53
NCOR2 Q9Y618 1/20 0.53
NR4A2 P43354 1/20 0.50
TDP1 Q9NUW8 3/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
MMP1 P03956 1/20 0.48
HDAC1 Q13547 1/20 0.46
GAA P10253 1/20 0.46
CYP2C19 P33261 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8638370 0.85 NPC1 (0.59) NPC1RAB9AALDH1A1HDAC3NCOR2
SCHEMBL8989372 0.85 NPC1 (0.59) NPC1RAB9AHDAC3NCOR2L3MBTL1
SCHEMBL7981993 0.84 HDAC3 (0.64) NPC1RAB9AHDAC3NCOR2
SCHEMBL9191952 0.83 HDAC3 (0.71) NPC1RAB9AHDAC3NCOR2HDAC1
SCHEMBL28840174 0.82 NPC1 (0.60) NPC1RAB9AALDH1A1HDAC3NCOR2
SCHEMBL23080107 0.81 NPC1 (0.59) NPC1RAB9AHDAC3NCOR2
SCHEMBL6763786 0.81 HDAC3 (0.74) NPC1RAB9AHDAC3NCOR2HDAC1
SCHEMBL3241593 0.80 NPC1 (0.57) NPC1RAB9AHDAC3NCOR2
SCHEMBL2037095 0.80 NPC1 (0.57) NPC1RAB9AALDH1A1HDAC3NCOR2
SCHEMBL3653038 0.79 HDAC3 (0.62) NPC1RAB9AHDAC3NCOR2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388544-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES VIVORYON THERAPEUTICS N.V. (DE) 2025-12-25 US disclosed
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases VIVORYON THERAPEUTICS N.V. (DE) 2023-04-20 US disclosed
CN-114585608-A Heteroaromatic inhibitors of astacin protease 维沃永治疗公众有限公司 2022-06-03 CN disclosed
EP-3986868-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES Vivoryon Therapeutics N.V. (DE) 2022-04-27 EP disclosed
WO-2020249760-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES VIVORYON THERAPEUTICS AG (DE) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122243-A1 Heteroaromatic inhibitors of astacin proteinases BMP1, DPEP1, MEP1A NPC1 980/4885RAB9A 3956/4885ALDH1A1 2800/4885
US-20250388544-A1 HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES BMP1, BMPR1A, BMPR1B NPC1 888/4885RAB9A 3505/4885ALDH1A1 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.